Biovest wins orphan drug status for cancer vax

Biovest International has announced that the FDA has granted orphan drug designation to BiovaxID, its personalized cancer vaccine, for a second lymphoma indication. "With promising clinical trials now complete in both follicular lymphoma and mantle cell lymphoma, we are preparing to seek regulatory approvals for BiovaxID in two separate indications," says Dr. Carlos Santos, Biovest's VP, product development & regulatory affairs. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.